Cowen Out Positive on AstraZeneca (AZN)

March 18, 2021 7:13 AM EDT
Get Alerts AZN Hot Sheet
Price: $57.89 -0.72%

Rating Summary:
    17 Buy, 7 Hold, 4 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 10 | Down: 11 | New: 50
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Cowen analyst Steve Scala reiterated an Outperform rating and $66.00 price target on AstraZeneca (NASDAQ: AZN) ahead of a year with numerous catalysts: Enhertu PI data in HER2-low BC, Farxiga PI data in HFpEF, and Lynparza PI data in mCRPC; potential approvals for anifrolumab in SLE and roxadustat in anemia; tezepelumab filing in severe asthma; and the closing of the Alexion transaction.

The analyst stated "AZN's new product momentum, R&D portfolio, and top-tier growth justify its admittedly rich valuation, particularly given opportunity for upside over time. Alexion further strengthens the outlook. News flow should be sector-leading in 2021, and low relative exposure to U.S. market makes AZN less vulnerable to potential reforms. These attributes should drive AZN shares to top performance in 2021". "Our target price of $66 is based on 24x our 2021 EPS estimate of $5.50. While this is a rich target PE multiple, no other pharma offers the attributes mentioned above, justifying this premium valuation, in our view."

For an analyst ratings summary and ratings history on AstraZeneca click here. For more ratings news on AstraZeneca click here.

Shares of AstraZeneca closed at $50.21 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Cowen & Co